Imidazolium Salt (DBZIM) Reduces Gliosis in Mice Treated with Neurotoxicant 2'-CH3-MPTP

CNS Neuroscience and Therapeutics

Volumn 17, Issue 3, 2011, Pages 148-157

  Ho, Gideon ^a   Kumar, Saravana ^a   Ke, Zhiyuan ^a   Chan, Hugh Hiu Nam ^a   Suhaimi, Nur Afidah Mohamed ^a   Kng, Yin Ling ^a   Zhang, Yugen ^a   Zhuo, Lang ^a  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Gliosis; Imidazolium salts; Neuroprotection; Neurotoxicity

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2' CH3 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GREEN FLUORESCENT PROTEIN; IMIDAZOLE DERIVATIVE; IMIDAZOLIUM SALT; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG STRUCTURE; GLIOSIS; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOUSE; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RETINA DISEASE; RETINA GLIOSIS; SCANNING LASER OPHTHALMOSCOPY; SUBSTANTIA NIGRA PARS COMPACTA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; DOPAMINE; DOPAMINE ANTAGONISTS; EYE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; GREEN FLUORESCENT PROTEINS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, TRANSGENIC; MPTP POISONING; NEOSTRIATUM; NEURONS; OPHTHALMOSCOPY; RETINA; SUPEROXIDE DISMUTASE;

EID: 79955706871     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00131.x     Document Type: Article

References (33)

1. Helmlinger D, Yvert G, Picaud S, et al. Progressive retinal degeneration and dysfunction in R6 Huntington's disease mice. Hum Mol Genet 2002;11:3351-3359.
2. Przedborski S, Jackson-Lewis V, Naini AB, et al. The Parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 2001;76:1265-1274.
3. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005;2:484-494.
4. Smeyne M, Jiao Y, Shepherd KR, Smeyne RJ. Glia cell number modulates sensitivity to MPTP in mice. Glia 2005;52:144-152.
5. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci 1990;13;296-302.
6. Haeggendal J, Malmfors T. Identification and cellular localization of the catecholamines in the retina and the choroid of the rabbit. Acta Physiol Scand 1965;64:58-66.
7. Iuvone PM, Galli CL, Garrison-Gund CK, Neff NH. Light stimulates tyrosine hydroxylase activity and dopamine synthesis in retinal amacrine neurons. Science 1978;202:901-902.
8. Wong C, Ishibashi T, Tucker G, Hamasaki D. Responses of the pigmented rabbit retina to NMPTP, a chemical inducer of Parkinsonism. Exp Eye Res 1985;40:509-519.
9. Mariani AP, Neff NH, Hadjiconstantinou M. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treatment decreases dopamine and increases lipofuscin in mouse retina. Neurosci Lett 1986;72:221-226.
10. Chen ST, Hsu JR, Hsu PC, Chuang JI. The retina as a novel in vivo model for studying the role of molecules of the Bcl-2 family in relation to MPTP neurotoxicity. Neurochem Res 2003;28:805-814.
11. Cuenca N, Herrero MT, Angulo A, et al. Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease. J Comp Neurol 2005;493:261-273.
12. Dyer MA, Cepko CL. Control of Muller glial cell proliferation and activation following retinal injury. Nature Neurosci 2000;3:873-880.
13. O'Callaghan JP. Assessment of neurotoxicity: Use of glial fibrillary acidic protein as a biomarker. Biomed Environ Sci 1991;4:197-206.
14. Ho G, Kumar S, Min XS, et al. Molecular imaging of retinal gliosis in transgenic mice induced by kainic acid neurotoxicity. Invest Ophthalmol Vis Sci 2009:50;2459-2464.
15. Kumar S, Ho G, Woo KM, Zhuo L. Achieving cellular resolution for in vivo retinal images of transgenic GFAP-GFP mice via image processing. Opt Exp 2008;16:8250-8262.
16. Zhuo L, Sun B, Zhang CL, et al. Live astrocytes visualized by green fluorescent protein in transgenic mice. Dev Biol 1997;187:36-42.
17. Seeliger MW, Beck SC, Pereyra-Munoz N, et al. In vivo confocal imaging of the retina in animal models using scanning laser ophthalmoscopy. Vision Res 2005;45:3512-3519.
18. Zhao L, Zhang C, Zhuo L, Zhang Y, Ying JY. Imidazolium salts: A mild reducing and antioxidative reagent. J Am Chem Soc 2008;130:12586-12587.
19. Abdel-Wahab MH. Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1, 2, 3, 6-tetrahydropyridine (2'-methyl-MPTP) in mice. J Biochem Mol Toxicol 2005;19:32-41.
20. Franklin K, Paxinos G. The mouse brain in stereotaxic coordinates, 2nd edition. San Francisco, CA Academic Press, 2001.
21. Sanchez-Pernaute R, Brownell AL, Jenkins BG, Isacson O. Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging. Toxicol Appl Pharmacol 2005;207:251-256.
22. O'Callaghan JP. Neurotypic and gliotypic proteins as biochemical markers of neurotoxicity. Neurotoxicol Teratol 1998;10:445-452.
23. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis 2006;23:77-86.
24. Olanow W, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999;22:123-144.
25. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39:889-909.
26. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005;11(Suppl 1):S9-S15.
27. Peng J, Stevenson FF, Doctrow SR, Andersen JK. Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial nigra: Implications for Parkinson disease. J Biol Chem 2005;280:29194-29198.
28. Grunblatt E, Mandel S, Maor G, Youdim MB. Gene expression analysis in N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: Effect of R-apomorphine. J Neurochem 2001;78:1-12.
29. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neurosci Lett 1994;180:147-150.
30. Jellinger KA. The role of iron in neurodegeneration: Prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 1999;14:115-140.
31. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 2001;78:1073-1082.
32. Choi JY, Park CS, Kim DJ, et al. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 2002;23:367-374.
33. Wu SS, Frucht SJ. Treatment of Parkinson's disease: What's on the horizon? CNS Drugs 2005;19:723-743.